First Drug for Pancreatic Cancer Approved | Little Rock News

FDA just approved a game-changing new pill for advanced pancreatic cancer — daraxonrasib, the first drug to target the KRAS mutation found in 90% of cases. Patients on it lived nearly twice as long (13.2 months vs. 6.7) with fewer severe side effects like rash and mouth sores. Priced at $39,800 per month, it’s already drawing public attention after being featured on 60 Minutes and fast-tracked for early access. This breakthrough could rewrite cancer treatment — once considered “undruggable,” the KRAS gene is now being tackled with a revolutionary molecular glue approach, possibly unlocking new therapies for other cancers too. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3b7b50da3d14e013